All In Biotech

Drug Trial Radar · NCT05580510

" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "

"An Open-label Clinical Trial to Evaluate the Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan in Adult Patients With Chronic Heart Failure With Reduced Ejection Fraction Associated With Congenital Heart Disease"

Last checked: Nov 20, 2026Latest source record: Nov 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

160

Planned (sponsor's estimate)

Start

Feb 6, 2023

Primary completion

Jul 28, 2023

Study completion Mar 29, 2024

Sponsor

Lead sponsor
Instituto Nacional de Cardiologia Ignacio ChavezAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Boehringer Ingelheim
First posted
Oct 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The treatment of adult patients with congenital heart disease (ACHD) and heart failure (HF) represents a great challenge since, to date, there is no standardized guideline for this specific population. Although new treatments for HF have been proposed, such as Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors and neprilisin and angiotensin receptor inhibitors, the benefit of these drugs in patients with HF associated with congenital heart disease in adults has not yet been demonstrated. For this reason, this study pretends to evaluate the efficacy of empagliflozin and sacubitril/valsartan in this population.

Conditions

  • Congenital Heart Disease
  • Heart Failure
  • Heart Failure With Reduced Ejection Fraction

Interventions

  • Sacubitril 49 MG / Valsartan 51 MG [Entresto] BIDDrug

    This group of patients will receive the conventional treatment of heart failure according to the "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure" and Sacubitril/Valsartan as an active comparator.

  • Empagliflozin 10 MG ODDrug

    This group of patients will receive the conventional treatment of heart failure according to the "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure" and Empagliflozin as an experimental drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 3D echocardiographic systemic ventricular end-diastolic volume indexTime frame: Twelve weeks
  2. 3D echocardiographic systemic ventricular end-systolic volume indexTime frame: Twelve weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institute of Cardiology Ignacio Chavez

    Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.